Market Overview

UPDATE: BMO Capital Markets Lowers PT on Covidien Ahead of Mallinckrodt Spin-Off

Related COV
Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression
Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids

In a report published Friday, BMO Capital Markets analyst Joanne K. Wuensch reiterated an Outperform rating on Covidien (NYSE: COV), but lowered the price target from $72.00 to $64.00.

In the report, BMO Capital Markets noted, “Covidien management has provided a tremendous amount of detail to aid investors with their evaluations of ‘RemainCo' and Mallinckrodt as standalone businesses, and we believe the transaction is well understood. Now the focus will shift to execution, against FY2Q13 results which raised some questions, and FY2013 guidance, which we view as reasonable, if not somewhat conservative. This said, our investment thesis on COV remains: the company's diversified portfolio and global footprint should allow it to manage through changes in healthcare, drive operating margin expansion, and deliver revenue above the market growth rate, looking for mid-single-digits that could be leveraged to high-single-digits/low-double-digits over time.”

Covidien closed on Thursday at $63.09.

Latest Ratings for COV

Nov 2014JefferiesMaintainsBuy
Oct 2014Morgan StanleyDowngradesOverweightEqual-Weight
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for COV
View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Joanne K. WuenschAnalyst Color Price Target Analyst Ratings


Related Articles (COV)

View Comments and Join the Discussion!

Partner Center